Title: VERU-111, a novel oral a and p tubulin inhibitor, has potent activity against paclitaxel sensitive and resistant prostate cancer. Presenter: Robert H Getzenberg, PhD Session Date and Time:Saturday, March 17, 2018 at 15:00-17:30 Location: Red Area, Room 3 About VERU-111 VERU-111 is a novel oral therapy tar